Nasopharyngeal carcinoma: an evolving paradigm
The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …
The global landscape of EBV-associated tumors
C Shannon-Lowe, A Rickinson - Frontiers in oncology, 2019 - frontiersin.org
Epstein-Barr virus (EBV), a gamma-1 herpesvirus, is carried as a life-long asymptomatic
infection by the great majority of individuals in all human populations. Yet this seemingly …
infection by the great majority of individuals in all human populations. Yet this seemingly …
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
HQ Mai, QY Chen, D Chen, C Hu, K Yang, J Wen, J Li… - Nature medicine, 2021 - nature.com
Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double …
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double …
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
LL Tang, YP Chen, CB Chen, MY Chen… - Cancer …, 2021 - Wiley Online Library
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02 …
FH Wang, XL Wei, J Feng, Q Li, N Xu, XC Hu… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal
carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and …
carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and …
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with extremely skewed
ethnic and geographic distributions. Increasing evidence indicates that targeting the tumor …
ethnic and geographic distributions. Increasing evidence indicates that targeting the tumor …
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
Y Wang, J Du, Z Gao, H Sun, M Mei, Y Wang… - British journal of …, 2023 - nature.com
Immune checkpoint blockade therapy targeting programmed cell death protein 1 (PD-1) has
revolutionized the landscape of multiple human cancer types, including head and neck …
revolutionized the landscape of multiple human cancer types, including head and neck …
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
W Fang, Y Yang, Y Ma, S Hong, L Lin, X He… - The Lancet …, 2018 - thelancet.com
Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine
plus cisplatin, are generally considered the first-line standard of care for patients with …
plus cisplatin, are generally considered the first-line standard of care for patients with …